SLC5A2 and type 2 diabetes mellitus: SGLT2-inhibitor-associated DKA is more likely in patients withinsulin-deficient diabetes, including those with T2D, and may present witheuglycemic DKA due to the glucosuric effect of SGLT2 inhibition.